Dianthus Therapeutics DNTH Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $51.09M+124% | $22.79M-82.8% | $132.33M+761% | $15.37M-88.3% | ||
| $353.21M+39.9% | $252.45M+510% | $41.39M-31.2% | $60.13M+32.8% | ||
| $52K— | $0-100% | $294K-93.7% | $4.7M— | ||
| $5.09M+4.8% | $4.86M+49.2% | $3.26M+260% | $905K-76.0% | ||
| $409.44M+45.8% | $280.9M+58.3% | $177.45M+116% | $82.03M-54.6% | ||
| $296K+52.6% | $194K+4.9% | $185K+30.3% | $142K-98.1% | ||
| $1.34M-13.9% | $1.55M+153% | $615K-24.4% | $814K— | ||
| $110.14M+34.8% | $81.73M— | $0— | —— | ||
| $530.92M+42.0% | $374.01M+108% | $179.41M+116% | $83.11M-56.2% | ||
| $19.45M+48.8% | $13.07M+101% | $6.5M-1.6% | $6.61M-15.5% | ||
| $5.77M+202% | $1.91M— | $0-100% | $791K— | ||
| $367K+14.7% | $320K-23.3% | $417K+19.1% | $350K— | ||
| $30.73M+66.6% | $18.45M+91.6% | $9.63M+17.1% | $8.23M-24.3% | ||
| $1.02M-13.0% | $1.17M+597% | $168K-61.6% | $438K— | ||
| —— | $1.49M+155% | $585K-98.0% | $29.96M— | ||
| $37.52M+74.3% | $21.53M+104% | $10.54M+11.4% | $9.45M-45.2% | ||
| $0— | $0— | $0— | $0— | ||
| $43K+38.7% | $31K+107% | $15K— | $0-100% | ||
| $829.6M+57.5% | $526.73M+104% | $258.23M+15,447% | $1.66M-99.7% | ||
| -$336.73M-93.1% | -$174.39M-95.0% | -$89.42M-95.0% | -$45.87M+85.9% | ||
| $489K+361% | $106K+126% | $47K+129% | -$161K-437% | ||
| $493.4M+40.0% | $352.48M+109% | $168.87M+481% | -$44.37M-157% | ||
| $530.92M+42.0% | $374.01M+108% | $179.41M+116% | $83.11M-56.2% | ||
| $1.34M-13.9% | $1.55M+153% | $615K-24.4% | $814K— | ||
| $110.14M+34.8% | $81.73M— | $0— | —— | ||
| $1.34M-13.9% | $1.55M+153% | $615K-24.4% | $814K— | ||
| $9.72M+0.9% | $9.63M+734% | $1.15M+854% | $121K— | ||
| $353.21M+39.9% | $252.45M+510% | $41.39M-31.2% | $60.13M— | ||
| $1.34M-13.9% | $1.55M+153% | $615K-24.4% | $814K— | ||
| $19.45M+48.8% | $13.07M+101% | $6.5M-1.6% | $6.61M— | ||
| $19.45M+48.8% | $13.07M+101% | $6.5M-1.6% | $6.61M— | ||
| $1.19M+148% | $479K— | $0-100% | $100K— | ||
| $5.77M+202% | $1.91M— | $0-100% | $791K— | ||
| $1.39M-7.0% | $1.49M+155% | $585K-98.0% | $29.96M— | ||
| $829.6M+57.5% | $526.73M+104% | $258.23M+15,447% | $1.66M-99.7% | ||
| $43K+38.7% | $31K+107% | $15K— | $0-100% | ||
| $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dianthus Therapeutics cover its short-term obligations?
- Its current ratio is 29.25 — current assets exceed current liabilities.
- Where does Dianthus Therapeutics's balance sheet data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.